

Amgen becomes a new member of CQDM

20 November 2018 | News

The Québec government firmly believes in the importance of coordinating biopharmaceutical research and will continue to support partnership initiatives that establish Québec as an important player in the development of innovative treatments



CQDM is pleased to welcome Amgen as a new member of its biopharmaceutical research consortium established to identify and invest in highly innovative biopharmaceutical research projects in Quebec and Canada with the ultimate goal of enabling the development of better treatments for patients.

This announcement was made at CQDM's 10th Anniversary Forum in the presence of over 300 stakeholders of the life sciences industry.

"The Québec government firmly believes in the importance of coordinating biopharmaceutical research and will continue to support partnership initiatives that establish Québec as an important player in the development of innovative treatments. Bringing Amgen on board with CQDM is in line with our desire to encourage partnerships and increase the economic spinoffs associated with the innovations that result."

"We are delighted to welcome Amgen at CQDM. It is world-leading biopharmaceutical companies who will bring key expertise to the development of the next generation of innovative technologies that are essential to the growth of our economy," said Diane Gosselin, President, and CEO of CQDM.

"We are thrilled to be officially joining CQDM's biopharmaceutical research consortium," stated Philip Tagari, Amgen's Vice President of Therapeutic Discovery. "Amgen has long recognized the high-quality research that emerges out of Quebec. In fact, some of the clinical science that supported the development of Amgen's most recent cardiovascular drug, Repatha®, was undertaken at the Montreal Clinical Research Institute. From regenerative medicine, to stem cell manufacturing, to artificial intelligence, Quebec is leading in many ways and we are excited about the partnership opportunities that CQDM offers."

"The Government of Quebec has long recognized the importance of the biopharmaceutical industry to its economy," said

Francesco Di Marco, Vice President and General Manager of Amgen Canada. "Our investment in CQDM is recognition of the importance of Quebec as a partner in growing the life sciences sector in Canada. CQDM's research consortium brings together local emerging companies, great science and the resources of multinational enterprises for the benefit of the patients we serve. We are extremely excited about what we can accomplish together."